LION-formulated, repRNA vaccination against HIV-1 and ZIKV successfully produced a robust immunological response in pregnant rabbits; maternal antibodies were transferred in utero to newborn kits Findings published in the peer-reviewed journal Molecular Therapy...

Goal ‘to change the cancer research narrative in Africa’ by applying HDT Bio’s advanced technology to help reduce inequalities in health care PRETORIA, SOUTH AFRICA and SEATTLE, WA (January 30, 2023) – HDT Bio Corp., a developer of immunotherapies for infectious...

UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV) The 5-year $59M prototype project will develop...

SEATTLE--HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today it has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and...

SEATTLE, WA (November 1, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today CEO Steven Reed will give a corporate presentation on Nov. 8, 3 pm, Fourth Floor, (Adams) at the BioFuture Investor Conference at the...